Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Amortization of Deferred Charges (2017 - 2023)

Historic Amortization of Deferred Charges for Neurocrine Biosciences (NBIX) over the last 6 years, with Q4 2023 value amounting to $100000.0.

  • Neurocrine Biosciences' Amortization of Deferred Charges changed N/A to $100000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $700000.0, marking a year-over-year change of. This contributed to the annual value of $700000.0 for FY2023, which is 4166.67% down from last year.
  • Latest data reveals that Neurocrine Biosciences reported Amortization of Deferred Charges of $100000.0 as of Q4 2023.
  • Neurocrine Biosciences' Amortization of Deferred Charges' 5-year high stood at $400000.0 during Q2 2019, with a 5-year trough of $100000.0 in Q4 2023.
  • For the 4-year period, Neurocrine Biosciences' Amortization of Deferred Charges averaged around $292307.7, with its median value being $300000.0 (2019).
  • The largest annual percentage gain for Neurocrine Biosciences' Amortization of Deferred Charges in the last 5 years was 2861.74% (2019), contrasted with its biggest fall of 1017.96% (2019).
  • Quarter analysis of 4 years shows Neurocrine Biosciences' Amortization of Deferred Charges stood at $400000.0 in 2019, then changed by 0.0% to $400000.0 in 2020, then dropped by 25.0% to $300000.0 in 2021, then plummeted by 66.67% to $100000.0 in 2023.
  • Its Amortization of Deferred Charges stands at $100000.0 for Q4 2023, versus $200000.0 for Q3 2023 and $200000.0 for Q2 2023.